Market Place
Sourcing Support
All News #Library
Rare Diseases
Larimar backs skin biomarker in Friedreich’s ataxia
30 Apr 2026 //
FIRSTWORD PHARMA
Larimar Pharma Gets FDA Breakthrough Status For Nomlabofusp
24 Feb 2026 //
GLOBENEWSWIRE
Larimar Therapeutics Updates Nomlabofusp Program
29 Sep 2025 //
GLOBENEWSWIRE
Larimar`s Nomlabofusp Shows Hope in Friedreich’s Ataxia
08 Jul 2025 //
GLOBENEWSWIRE
Larimar Therapeutics Gets FDA Feedback on Nomlabofusp BLA Details
23 Jun 2025 //
GLOBENEWSWIRE
Larimar Sets Call on Nomlabofusp for Friedreich’s Ataxia
20 Jun 2025 //
GLOBENEWSWIRE
Larimar Doses Adolescents In Study For Friedreich’s Ataxia
23 Jan 2025 //
GLOBENEWSWIRE
First rare disease therapies chosen for FDA START programme
05 Jun 2024 //
PHARMAPHORUM
FDA picks Denali, Neurogene and more for rare disease program
04 Jun 2024 //
FIERCE BIOTECH
Larimar In FDA START Pilot For Nomlabofusp In Friedreich`s Ataxia
30 May 2024 //
GLOBENEWSWIRE
Larimar to kick off higher dose of lead rare disease drug, initiate OLE trial
25 Jul 2023 //
ENDPTS
Larimar to Participate in the Guggenheim Genomic Medicines and Rare Disease Days
28 Mar 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.